Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

Brief Summary: It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Recruitment & Eligibility

Inclusion Criteria

over 19 years
the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up
the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer

Exclusion Criteria

gastrectomy history
advanced gastric cancer (impossible to get the gastrectomy)
Helicobacter eradication history
the patients who have chronic disease
cancer patients except gastric cancer within 6 months
who cannot perform this study according to research's decision
who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)

Arm && Interventions

Group	Intervention	Description
gastritis and pepsinogen	pepsinogen and gastrin	-

Primary Outcome Measures

Name	Time	Method
the change of pepsinogen level before and after H. pylori eradication	baseline and 6 months	to compare the change of the pepsinogen level before and after H. pylori eradication and evaluate the correlation between the pepsinogen level and the atrophic gastritis

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial